Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)

NICE technology appraisals [TA293] Published date:

This guidance updates and replaces NICE technology appraisal 205 (published in October 2010)

What has NICE said?

NICE recommends eltrombopag as a possible treatment for some adults with chronic immune (idiopathic) thrombocytopenic purpura (which is sometimes shortened to chronic ITP).

Who can have eltrombopag?

You should be able to have eltrombopag if you have had your spleen removed, or if you have not had your spleen removed because you can’t have the operation, only if:

  • your chronic ITP has not improved even though you have tried other available treatments, or
  • you have severe chronic ITP and a high risk of bleeding that needs frequent courses of emergency treatment.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.

NICE recommended eltrombopag because it is effective and costs less than other treatments available on the NHS.

Get involved